Related Experiment Video

Updated: Jan 29, 2026

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.3K

Pharmacotherapeutic options for patients with refractory breast cancer

Palma Fedele1, Mariangela Ciccarese2, Giammarco Surico3

  • 1a Medical Oncology & Breast Unit , "Antonio Perrino" Hospital , Brindisi , Italy.

Expert Opinion on Pharmacotherapy
|February 8, 2019
PubMed
Abstract

Insights

Therapy resistance is a major challenge in breast cancer (BC) treatment. Advances in targeted therapies have improved outcomes, but further research is needed to identify resistance biomarkers and optimize treatment sequences.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Therapy resistance is a significant challenge across all breast cancer (BC) subtypes.
  • Recent advancements in molecularly targeted therapies have improved patient outcomes.
  • Triple-negative breast cancer (TNBC) presents unique challenges due to early resistance and limited targeted options.

Purpose of the Study:

  • To review current pharmacotherapeutic options for refractory breast cancer.
  • To provide expert perspectives on managing treatment resistance in BC.
  • To highlight unmet needs in refractory breast cancer treatment.

Main Methods:

  • Literature review of current treatment strategies for refractory breast cancer.
  • Analysis of mechanisms of therapeutic resistance in BC.
  • Expert opinion on future directions in BC pharmacotherapy.

Main Results:

  • Targeted therapies have shown promise in improving outcomes for refractory BC patients.
  • Significant progress has been made in understanding BC resistance mechanisms.
  • Unresolved issues include identifying resistance biomarkers and determining optimal treatment sequences.

Conclusions:

  • Personalized treatment strategies are crucial for overcoming BC resistance.
  • Biomarker discovery is essential for tailoring therapies and minimizing toxicity.
  • Further research is needed to establish optimal treatment sequencing for refractory BC.
Keywords:
antiHer2 therapybreast cancerde novo resistanceendocrine therapyimmunotherapysecondary resistancetargeted therapies

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.0K
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.9K

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.2K
Patient-centered Care01:13

Patient-centered Care

Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.0K
What is Cancer?02:12

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.4K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
269
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
263
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.0K